Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Indocyanine Green Fluorescent Molecular Imaging of the Gastrointestinal Tract
A Pilot Study of Indocyanine Green Fluorescent Molecular Imaging of the Gastrointestinal Tract
Status: Enrolling
Updated:  4/25/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Indocyanine Green Fluorescent Molecular Imaging of the Gastrointestinal Tract
A Pilot Study of Indocyanine Green Fluorescent Molecular Imaging of the Gastrointestinal Tract
Status: Enrolling
Updated: 4/25/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Lapatinib and Cetuximab in Patients With Solid Tumors
A Phase I Study of Lapatinib and Cetuximab in Patients With Solid Tumors
Status: Enrolling
Updated:  5/14/2012
Georgetown University Medical Center
mi
from
Washington,
Lapatinib and Cetuximab in Patients With Solid Tumors
A Phase I Study of Lapatinib and Cetuximab in Patients With Solid Tumors
Status: Enrolling
Updated: 5/14/2012
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Dignity Therapy in mCRC to Increase Peaceful Awareness & Impact Goals of Care Decision-Making
Use of Dignity Therapy in Stage IV Colorectal Cancer Patients Receiving Chemotherapy to Increase Peaceful Awareness and Impact Goals of Care Decision-Making
Status: Enrolling
Updated:  5/17/2012
Northwestern University, Northwestern Memorial Faculty Foundation
mi
from
Chicago, IL
Dignity Therapy in mCRC to Increase Peaceful Awareness & Impact Goals of Care Decision-Making
Use of Dignity Therapy in Stage IV Colorectal Cancer Patients Receiving Chemotherapy to Increase Peaceful Awareness and Impact Goals of Care Decision-Making
Status: Enrolling
Updated: 5/17/2012
Northwestern University, Northwestern Memorial Faculty Foundation
mi
from
Chicago, IL
Click here to add this to my saved trials
Vitamin E Supplements in Treating Patients Undergoing Surgery for Colorectal Cancer
A Randomized Study to Investigate the Presence of Tocopherol Metabolites in the Colon
Status: Enrolling
Updated:  6/12/2012
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Vitamin E Supplements in Treating Patients Undergoing Surgery for Colorectal Cancer
A Randomized Study to Investigate the Presence of Tocopherol Metabolites in the Colon
Status: Enrolling
Updated: 6/12/2012
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
Genetic Events Leading to APC-Dependent Colon Cancer in High-Risk Families; a Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
Status: Enrolling
Updated:  6/14/2012
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
Genetic Events Leading to APC-Dependent Colon Cancer in High-Risk Families; a Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
Status: Enrolling
Updated: 6/14/2012
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux®) in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  6/18/2012
Local Institution
mi
from
Minneapolis, MN
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux®) in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 6/18/2012
Local Institution
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux®) in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  6/18/2012
Nebraska Methodist Hospital
mi
from
Omaha, NE
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux®) in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 6/18/2012
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux®) in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  6/18/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux®) in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 6/18/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux®) in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  6/18/2012
Local Institution
mi
from
Philadelphia, PA
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux®) in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 6/18/2012
Local Institution
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux®) in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  6/18/2012
Local Institution
mi
from
Houston, TX
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux®) in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 6/18/2012
Local Institution
mi
from
Houston, TX
Click here to add this to my saved trials
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux®) in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  6/18/2012
University of Wisconsin
mi
from
Madison, WI
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux®) in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 6/18/2012
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
BKM120 in Cancers With PIK3CA Activating Mutations
An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations
Status: Enrolling
Updated:  7/12/2012
Massachusetts General Hospital
mi
from
Boston, MA
BKM120 in Cancers With PIK3CA Activating Mutations
An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations
Status: Enrolling
Updated: 7/12/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Johns Hopkins Interactive eGuide to Colonoscopy and Ipad Office Education to Improve Colonoscopy
Integration of an Electronic Education System Into Colonoscopy: Improving Education, Consent and Compliance of Patients at Colonoscopy With an Ipad-based Secure Video Intervention
Status: Enrolling
Updated:  7/19/2012
Johns Hopkins University
mi
from
Baltimore, MD
Johns Hopkins Interactive eGuide to Colonoscopy and Ipad Office Education to Improve Colonoscopy
Integration of an Electronic Education System Into Colonoscopy: Improving Education, Consent and Compliance of Patients at Colonoscopy With an Ipad-based Secure Video Intervention
Status: Enrolling
Updated: 7/19/2012
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer
BrUOG- Phase 1-233: A Phase I Study of Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer
Status: Enrolling
Updated:  7/24/2012
The Miriam Hospital
mi
from
Providence, RI
Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer
BrUOG- Phase 1-233: A Phase I Study of Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer
Status: Enrolling
Updated: 7/24/2012
The Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Eastern Regional Medical Center
mi
from
Philadelphia, PA
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Eastern Regional Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
University of California, Irvine
mi
from
Irvine, CA
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
University of California, Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
UMDNJ
mi
from
Newark, NJ
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
UMDNJ
mi
from
Newark, NJ
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Beth Israel Med Ctr
mi
from
New York, NY
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Mount Sinai School of Medicine
mi
from
New York, NY
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep
Phase 4 of Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep
Status: Enrolling
Updated:  9/27/2012
Rush Unversity Medical Center
mi
from
Chicago, IL
Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep
Phase 4 of Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep
Status: Enrolling
Updated: 9/27/2012
Rush Unversity Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer
A Phase II Evaluation of Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer
Status: Enrolling
Updated:  10/1/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer
A Phase II Evaluation of Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer
Status: Enrolling
Updated: 10/1/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  10/2/2012
Clinical Research Facility
mi
from
Phoenix, AZ
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 10/2/2012
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  10/2/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 10/2/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  10/2/2012
Clinical Research Facility
mi
from
Chattanooga, TN
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 10/2/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Confocal Endomicroscopy for GI Neoplasia Study
Confocal Endomicroscopy for GI Neoplasia Study
Status: Enrolling
Updated:  10/11/2012
Mayo Clinic Florida
mi
from
Jacksonville, FL
Confocal Endomicroscopy for GI Neoplasia Study
Confocal Endomicroscopy for GI Neoplasia Study
Status: Enrolling
Updated: 10/11/2012
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Pilot Study of Docosahexaenoic Acid (DHA) in Obese Menopausal Women
Docosahexaenoic Acid (DHA) Reduces Inflammation and Aromatase Expression in Subcutaneous Fat and Inflammation in the Rectosigmoid Mucosa in Obese Postmenopausal Women: A Pilot Study
Status: Enrolling
Updated:  10/17/2012
Rockefeller University
mi
from
New York, NY
A Pilot Study of Docosahexaenoic Acid (DHA) in Obese Menopausal Women
Docosahexaenoic Acid (DHA) Reduces Inflammation and Aromatase Expression in Subcutaneous Fat and Inflammation in the Rectosigmoid Mucosa in Obese Postmenopausal Women: A Pilot Study
Status: Enrolling
Updated: 10/17/2012
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
Polyp Detection With The Peerscope System™
Polyp Detection With The Peerscope System™: A Randomized Tandem Colonoscopy Study
Status: Enrolling
Updated:  11/4/2012
North Shore Gasstroenterology Assoiates, P.C.
mi
from
NY, NY
Polyp Detection With The Peerscope System™
Polyp Detection With The Peerscope System™: A Randomized Tandem Colonoscopy Study
Status: Enrolling
Updated: 11/4/2012
North Shore Gasstroenterology Assoiates, P.C.
mi
from
NY, NY
Click here to add this to my saved trials
Polyp Detection With The Peerscope System™
Polyp Detection With The Peerscope System™: A Randomized Tandem Colonoscopy Study
Status: Enrolling
Updated:  11/4/2012
Southshore Gasstroenterology, P.C
mi
from
NY, NY
Polyp Detection With The Peerscope System™
Polyp Detection With The Peerscope System™: A Randomized Tandem Colonoscopy Study
Status: Enrolling
Updated: 11/4/2012
Southshore Gasstroenterology, P.C
mi
from
NY, NY
Click here to add this to my saved trials
Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers
Randomized Clinical Trial Evaluating the Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers
Status: Enrolling
Updated:  12/6/2012
Tufts Medical Center
mi
from
Boston, MA
Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers
Randomized Clinical Trial Evaluating the Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers
Status: Enrolling
Updated: 12/6/2012
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
OSI-906 and Irinotecan in Patients With Advanced Cancer
A Phase I/IB Study of OSI-906 and Irinotecan in Patients With Advanced Cancer With Expanded Cohorts of Patients With Colorectal Cancer Stratified by the OSI-906 Integrated Classifier
Status: Enrolling
Updated:  12/28/2012
University of Colorado Denver
mi
from
Aurora, CO
OSI-906 and Irinotecan in Patients With Advanced Cancer
A Phase I/IB Study of OSI-906 and Irinotecan in Patients With Advanced Cancer With Expanded Cohorts of Patients With Colorectal Cancer Stratified by the OSI-906 Integrated Classifier
Status: Enrolling
Updated: 12/28/2012
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
CROSSROAD II: Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening
Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening
Status: Enrolling
Updated:  1/23/2013
OHSU Knight Cancer Institute
mi
from
Portland, OR
CROSSROAD II: Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening
Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening
Status: Enrolling
Updated: 1/23/2013
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer
An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of 5 FU/FA and Oxaliplatin (Modified FOLFOX 6) in Combination With IMC-1121B or IMC-18F1 or Without Investigational Therapy as Second Line Therapy in Patients With Metastatic Colorectal Cancer Following Disease Progression on First Line Irinotecan-based Therapy
Status: Enrolling
Updated:  1/24/2013
ImClone Investigational Site
mi
from
Cincinnati, OH
A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer
An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of 5 FU/FA and Oxaliplatin (Modified FOLFOX 6) in Combination With IMC-1121B or IMC-18F1 or Without Investigational Therapy as Second Line Therapy in Patients With Metastatic Colorectal Cancer Following Disease Progression on First Line Irinotecan-based Therapy
Status: Enrolling
Updated: 1/24/2013
ImClone Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer
An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of 5 FU/FA and Oxaliplatin (Modified FOLFOX 6) in Combination With IMC-1121B or IMC-18F1 or Without Investigational Therapy as Second Line Therapy in Patients With Metastatic Colorectal Cancer Following Disease Progression on First Line Irinotecan-based Therapy
Status: Enrolling
Updated:  1/24/2013
ImClone Investigational Site
mi
from
Charleston, SC
A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer
An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of 5 FU/FA and Oxaliplatin (Modified FOLFOX 6) in Combination With IMC-1121B or IMC-18F1 or Without Investigational Therapy as Second Line Therapy in Patients With Metastatic Colorectal Cancer Following Disease Progression on First Line Irinotecan-based Therapy
Status: Enrolling
Updated: 1/24/2013
ImClone Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer
An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of 5 FU/FA and Oxaliplatin (Modified FOLFOX 6) in Combination With IMC-1121B or IMC-18F1 or Without Investigational Therapy as Second Line Therapy in Patients With Metastatic Colorectal Cancer Following Disease Progression on First Line Irinotecan-based Therapy
Status: Enrolling
Updated:  1/24/2013
ImClone Investigational Site
mi
from
Memphis, TN
A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer
An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of 5 FU/FA and Oxaliplatin (Modified FOLFOX 6) in Combination With IMC-1121B or IMC-18F1 or Without Investigational Therapy as Second Line Therapy in Patients With Metastatic Colorectal Cancer Following Disease Progression on First Line Irinotecan-based Therapy
Status: Enrolling
Updated: 1/24/2013
ImClone Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Pilot Study of a Geriatric Intervention After Colorectal and Lung Cancer Surgery
Pilot Study of a Geriatric Intervention After Colorectal and Lung Cancer Surgery
Status: Enrolling
Updated:  1/29/2013
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Pilot Study of a Geriatric Intervention After Colorectal and Lung Cancer Surgery
Pilot Study of a Geriatric Intervention After Colorectal and Lung Cancer Surgery
Status: Enrolling
Updated: 1/29/2013
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI
A Prospective, Randomized, Crossover Evaluation of the Effect of Atorvastatin on the Pharmacokinetics of Irinotecan in Colorectal Cancer Patients Receiving FOLFIRI
Status: Enrolling
Updated:  2/15/2013
Univ. of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI
A Prospective, Randomized, Crossover Evaluation of the Effect of Atorvastatin on the Pharmacokinetics of Irinotecan in Colorectal Cancer Patients Receiving FOLFIRI
Status: Enrolling
Updated: 2/15/2013
Univ. of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Banner MD Anderson Cancer Center
mi
from
Gilbert, AZ
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Banner MD Anderson Cancer Center
mi
from
Gilbert, AZ
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Genesis Cancer Center
mi
from
Hot Springs, AZ
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Genesis Cancer Center
mi
from
Hot Springs, AZ
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Arizona Clinical Research Center
mi
from
Tucson, AZ
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Arizona Clinical Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
University of California at San Diego
mi
from
San Diego, CA
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
University of California at San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
UC Irvine Medical Center, Division of Hematology/Oncology
mi
from
Orange, CA
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
UC Irvine Medical Center, Division of Hematology/Oncology
mi
from
Orange, CA
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Desert Hematology Oncology Medical Group
mi
from
Rancho Mirage, CA
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Desert Hematology Oncology Medical Group
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Mountain Blue Cancer Care Center
mi
from
Wheat Ridge, CO
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Mountain Blue Cancer Care Center
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Stamford Hospital
mi
from
Stamford, CT
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Stamford Hospital
mi
from
Stamford, CT
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
University Cancer Institute
mi
from
Boyton Beach, FL
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
University Cancer Institute
mi
from
Boyton Beach, FL
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
University of Florida, Davis Cancer Center (VA)
mi
from
Gainesville, FL
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
University of Florida, Davis Cancer Center (VA)
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Cleveland Clinic Florida
mi
from
Weston, FL
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Cleveland Clinic Florida
mi
from
Weston, FL
Click here to add this to my saved trials